Размер шрифта
Цветовая схема
Изображения
Форма
Межсимвольный интервал
Межстрочный интервал
стандартные настройки
обычная версия сайта
закрыть
  • Вход
  • Регистрация
  • Помощь
Выбрать БД
Простой поискРасширенный поискИстория поисков
Главная / Результаты поиска

Atherosclerosis: Perspectives of anti-inflammatory therapy

Насонов Е. Л., Попкова Т. В.
Терапевтический архив
Т. 90, Вып. 5, С. 4-12
Опубликовано: 2018
Тип ресурса: Статья

DOI:10.26442/terarkh20189054-12

Аннотация:
According to modern ideas, chronic low-grade inflammation, which development is associated with uncontrolled activation of both innate and adaptive immunity, plays a fundamental role in all stages of the atherosclerotic process. The contribution of inflammation to the development of atherosclerotic vascular lesions attracts attention to the similarity of the mechanisms of immunopathogenesis of atherosclerosis and classic inflammatory rheumatic disease - rheumatoid arthritis. In the aspect of participation in the pathogenesis of atherosclerotic vascular lesions and as a promising therapeutic "target" of particular interest is interleukin-1β (IL-1β), which plays an important role in the development of many acute and chronic immunosuppressive diseases. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "Pro-atherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. The mechanisms of atherosclerosis a
Ключевые слова:
Atherosclerosis; Canakinumab; Cytokines; Interleukin-1; Rheumatoid arthritis; Tocilizumab
antiinflammatory agent; interleukin 1beta; atherosclerosis; human; immunology; inflammation; thrombosis; Anti-Inflammatory Agents; Atherosclerosis; Humans; Inflammation; Interleukin-1beta; Thrombosis
Язык текста: Русский
ISSN: 2309-5342
Насонов Е. Л. Евгений Львович 1948-
Попкова Т. В.
Nasonov E. L. Evgenij L`vovich 1948-
Popkova T. V.
Atherosclerosis: Perspectives of anti-inflammatory therapy
Текст визуальный непосредственный
Терапевтический архив
Медицинское маркетинговое агентство "МедиаМедика"
Т. 90, Вып. 5 С. 4-12
2018
Статья
Atherosclerosis Canakinumab Cytokines Interleukin-1 Rheumatoid arthritis Tocilizumab
antiinflammatory agent interleukin 1beta atherosclerosis human immunology inflammation thrombosis Anti-Inflammatory Agents Atherosclerosis Humans Inflammation Interleukin-1beta Thrombosis
According to modern ideas, chronic low-grade inflammation, which development is associated with uncontrolled activation of both innate and adaptive immunity, plays a fundamental role in all stages of the atherosclerotic process. The contribution of inflammation to the development of atherosclerotic vascular lesions attracts attention to the similarity of the mechanisms of immunopathogenesis of atherosclerosis and classic inflammatory rheumatic disease - rheumatoid arthritis. In the aspect of participation in the pathogenesis of atherosclerotic vascular lesions and as a promising therapeutic "target" of particular interest is interleukin-1β (IL-1β), which plays an important role in the development of many acute and chronic immunosuppressive diseases. The mechanisms of atherosclerosis associated with IL-1β determine the ability of cholesterol crystals and other "Pro-atherogenic" factors to induce the synthesis of IL-1β by activating NLRP3 inflammasome. The mechanisms of atherosclerosis a